Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
261M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
19.4M
-
Shares change
-
+302K
-
Total reported value, excl. options
-
$362M
-
Value change
-
+$2.74M
-
Number of buys
-
24
-
Number of sells
-
-16
-
Price
-
$18.62
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) as of Q3 2021
53 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share as of Q3 2021.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.4M shares
of 261M outstanding shares and own 7.44% of the company stock.
Largest 10 shareholders include FMR LLC (5.76M shares), BlackRock Inc. (3.02M shares), FRANKLIN RESOURCES INC (1.31M shares), Nantahala Capital Management, LLC (1.25M shares), UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO (1.15M shares), Artal Group S.A. (1.04M shares), VANGUARD GROUP INC (806K shares), Sands Capital Ventures, LLC (725K shares), TimesSquare Capital Management, LLC (651K shares), and Alphabet Inc. (641K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.